Vernalis Cancer Company Intelligence Report
 
Report

Vernalis Cancer Company Intelligence ReportEspicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

From:
$195
 
Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Vernalis is a research and development stage biopharmaceuticals company, focusing on oncology, neurosciences/central nervous system disorders, bacterial infections and inflammatory diseases.

Report Details:
Publisher:
Espicom
Type:
Market Briefing - September 2005
Number of pages:
8
First Publication Date:
13/9/2005
 
 
 
Copyright © Chiltern Magazine Services Ltd | Email: admin@cmsinfo.com | Tel: +(1) 508 861 0401